Kiniksa Pharmaceuticals (KNSA) Competitors $20.59 +0.10 (+0.49%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KNSA vs. CYTK, TGTX, VKTX, BBIO, CRNX, KRYS, ACLX, ADMA, RARE, and BHVNShould you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Cytokinetics (CYTK), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), BridgeBio Pharma (BBIO), Crinetics Pharmaceuticals (CRNX), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals vs. Cytokinetics TG Therapeutics Viking Therapeutics BridgeBio Pharma Crinetics Pharmaceuticals Krystal Biotech Arcellx ADMA Biologics Ultragenyx Pharmaceutical Biohaven Cytokinetics (NASDAQ:CYTK) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability. Does the media favor CYTK or KNSA? In the previous week, Cytokinetics had 11 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 13 mentions for Cytokinetics and 2 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 1.46 beat Cytokinetics' score of 0.85 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiniksa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in CYTK or KNSA? Cytokinetics received 637 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 79.74% of users gave Cytokinetics an outperform vote while only 64.89% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCytokineticsOutperform Votes80779.74% Underperform Votes20520.26% Kiniksa PharmaceuticalsOutperform Votes17064.89% Underperform Votes9235.11% Which has more volatility & risk, CYTK or KNSA? Cytokinetics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Which has stronger earnings and valuation, CYTK or KNSA? Kiniksa Pharmaceuticals has higher revenue and earnings than Cytokinetics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$3.22M1,791.66-$526.24M-$5.38-9.08Kiniksa Pharmaceuticals$384.10M3.87$14.08M-$0.14-147.07 Is CYTK or KNSA more profitable? Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Kiniksa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-17,906.25% N/A -50.21% Kiniksa Pharmaceuticals -2.36%-7.31%-5.95% Do analysts recommend CYTK or KNSA? Cytokinetics currently has a consensus price target of $84.07, suggesting a potential upside of 72.02%. Kiniksa Pharmaceuticals has a consensus price target of $36.60, suggesting a potential upside of 77.76%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiniksa Pharmaceuticals is more favorable than Cytokinetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 4 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.75Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in CYTK or KNSA? 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 3.4% of Cytokinetics shares are owned by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryKiniksa Pharmaceuticals beats Cytokinetics on 10 of the 18 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.49B$6.57B$5.10B$9.07BDividend YieldN/A2.97%4.90%4.21%P/E Ratio-147.0610.5591.0817.15Price / Sales3.87195.381,113.51116.81Price / CashN/A57.1642.2637.86Price / Book3.305.104.784.78Net Income$14.08M$151.51M$119.77M$225.60M7 Day Performance1.93%-2.12%-1.87%-1.23%1 Month Performance-2.51%-3.11%11.46%3.07%1 Year Performance14.33%11.52%30.53%16.48% Kiniksa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals2.5294 of 5 stars$20.59+0.5%$36.60+77.8%+15.4%$1.49B$384.10M-147.06220Positive NewsCYTKCytokinetics4.1299 of 5 stars$49.22+1.2%$83.93+70.5%+36.8%$5.81B$3.22M-9.04250Analyst ForecastTGTXTG Therapeutics4.3117 of 5 stars$34.56+7.9%$40.67+17.7%+87.1%$5.38B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2928 of 5 stars$48.02+2.1%$106.75+122.3%+139.8%$5.35BN/A-51.5620Analyst ForecastGap UpBBIOBridgeBio Pharma4.6924 of 5 stars$27.75+0.9%$47.69+71.9%-30.7%$5.24B$217.77M-11.63400Positive NewsCRNXCrinetics Pharmaceuticals4.0687 of 5 stars$54.28+1.2%$70.82+30.5%+55.4%$5.03B$1.04M-14.39210Positive NewsKRYSKrystal Biotech4.5152 of 5 stars$171.78+5.0%$206.67+20.3%+45.9%$4.94B$50.70M92.45229Analyst ForecastACLXArcellx3.1314 of 5 stars$85.25+1.7%$105.93+24.3%+49.1%$4.61B$155.82M-118.03130Positive NewsADMAADMA Biologics3.776 of 5 stars$19.05+2.5%$21.25+11.5%+325.4%$4.50B$382.81M68.32530Positive NewsGap DownRAREUltragenyx Pharmaceutical4.4437 of 5 stars$46.05+0.6%$87.46+89.9%-2.6%$4.25B$434.25M-7.081,276Analyst ForecastNews CoverageBHVNBiohaven3.7123 of 5 stars$41.14+6.9%$63.00+53.1%-4.4%$4.16B$462.51M-4.11239Analyst Forecast Related Companies and Tools Related Companies Cytokinetics Alternatives TG Therapeutics Alternatives Viking Therapeutics Alternatives BridgeBio Pharma Alternatives Crinetics Pharmaceuticals Alternatives Krystal Biotech Alternatives Arcellx Alternatives ADMA Biologics Alternatives Ultragenyx Pharmaceutical Alternatives Biohaven Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KNSA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KNSA Stock Alerts